The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
The selectivity of protein kinase inhibitors: a further update
Open accessAbstract
The specificities of 65 compounds reported to be relatively specific inhibitors of protein kinases have been profiled against a panel of 70–80 protein kinases. On the basis of this information, the effects of compounds that we have studied in cells and other data in the literature, we recommend the use of the following small-molecule inhibitors: SB 203580/SB202190 and BIRB 0796 to be used in parallel to assess the physiological roles of p38 MAPK (mitogen-activated protein kinase) isoforms, PI-103 and wortmannin to be used in parallel to inhibit phosphatidylinositol (phosphoinositide) 3-kinases, PP1 or PP2 to be used in parallel with Src-I1 (Src inhibitor-1) to inhibit Src family members; PD 184352 or PD 0325901 to inhibit MKK1 (MAPK kinase-1) or MKK1 plus MKK5, Akt-I-1/2 to inhibit the activation of PKB (protein kinase B/Akt), rapamycin to inhibit TORC1 [mTOR (mammalian target of rapamycin)–raptor (regulatory associated protein of mTOR) complex], CT 99021 to inhibit GSK3 (glycogen synthase kinase 3), BI-D1870 and SL0101 or FMK (fluoromethylketone) to be used in parallel to inhibit RSK (ribosomal S6 kinase), D4476 to inhibit CK1 (casein kinase 1), VX680 to inhibit Aurora kinases, and roscovitine as a pan-CDK (cyclin-dependent kinase) inhibitor. We have also identified harmine as a potent and specific inhibitor of DYRK1A (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A) in vitro. The results have further emphasized the need for considerable caution in using small-molecule inhibitors of protein kinases to assess the physiological roles of these enzymes. Despite being used widely, many of the compounds that we analysed were too non-specific for useful conclusions to be made, other than to exclude the involvement of particular protein kinases in cellular processes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., & Saltiel, A. R. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.46.27489 · Cited by 3,393
Self-citationWatterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132
Self-citationIdentification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015
Regulation of Myosin Phosphatase by Rho and Rho-Associated Kinase (Rho-Kinase)
Kimura, K., Ito, M., Amano, M., Chihara, K., Fukata, Y., Nakafuku, M., Yamamori, B., Feng, J., Nakano, T., Okawa, K., et al. (1996) · Science · doi:10.1126/science.273.5272.245 · Cited by 2,884
Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension
Uehata, M., Ishizaki, T., Satoh, H., Ono, T., Kawahara, T., Morishita, T., Tamakawa, H., Yamagami, K., Inui, J., Maekawa, M., et al. (1997) · Nature · doi:10.1038/40187 · Cited by 2,859
Hidaka, H., Inagaki, M., Kawamoto, S., & Sasaki, Y. (1984) · Biochemistry · doi:10.1021/bi00316a032 · Cited by 2,687
(1995) · FEBS Letters · doi:10.1016/0014-5793(95)00357-f · Cited by 2,086
Cited by
Items 101–168 of 168
Rac1 Regulates the Activity of mTORC1 and mTORC2 and Controls Cellular Size
Saci, A., Cantley, L. C., & Carpenter, C. L. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.03.017 · Cited by 275
Wnt/β-catenin signalling in prostate cancer
Kypta, R. M., & Waxman, J. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.116 · Cited by 275
Ihle, N. T., Lemos, R., Wipf, P., Yacoub, A., Mitchell, C., Siwak, D., Mills, G. B., Dent, P., Kirkpatrick, D. L., & Powis, G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-07-6656 · Cited by 274
Macintyre, A. N., Finlay, D., Preston, G., Sinclair, L. V., Waugh, C. M., Tamas, P., Feijoo, C., Okkenhaug, K., & Cantrell, D. A. (2011) · Immunity · doi:10.1016/j.immuni.2011.01.012 · Cited by 273
Will the Ubiquitin System Furnish as Many Drug Targets as Protein Kinases?
Cohen, P., & Tcherpakov, M. (2010) · Cell · doi:10.1016/j.cell.2010.11.016 · Cited by 271
Self-citationPearce, L. R., Alton, G. R., Richter, D. T., Kath, J. C., Lingardo, L., Chapman, J., Hwang, C., & Alessi, D. R. (2010) · Biochemical Journal · doi:10.1042/bj20101024 · Cited by 265
Self-citationDrugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic
Workman, P., Clarke, P. A., Raynaud, F. I., & van Montfort, R. L. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4355 · Cited by 264
RhoA and RhoC have distinct roles in migration and invasion by acting through different targets
Vega, F. M., Fruhwirth, G., Ng, T., & Ridley, A. J. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201011038 · Cited by 260
The Role of p38 MAPK and Its Substrates in Neuronal Plasticity and Neurodegenerative Disease
Corrêa, S. A. L., & Eales, K. L. (2012) · Journal of Signal Transduction · doi:10.1155/2012/649079 · Cited by 258
“Throughout this paper only the activation of p38α and p38β isoforms will be discussed mainly due to the fact that the p38 MAPK inhibitors, SB203580 and SB202190, can specifically block the activity of the p38α and p38β and do not inhibit p38γ and p38δ isoforms [12] and also due to the fact that only p38α and p38β isof…”
BackgroundProtein kinase inhibitors: contributions from structure to clinical compounds
Johnson, L. N. (2009) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583508004745 · Cited by 256
The specificities of small molecule inhibitors of the TGFß and BMP pathways
Vogt, J., Traynor, R., & Sapkota, G. P. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.06.019 · Cited by 256
Mitogen-Activated Protein Kinase Pathways in Osteoblasts
Greenblatt, M. B., Shim, J.-H., & Glimcher, L. H. (2013) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101512-122347 · Cited by 253
Mancini, S. J., Boyd, D., Katwan, O. J., Strembitska, A., Almabrouk, T. A., Kennedy, S., Palmer, T. M., & Salt, I. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-23420-4 · Cited by 240
Girotti, M. R., Lopes, F., Preece, N., Niculescu-Duvaz, D., Zambon, A., Davies, L., Whittaker, S., Saturno, G., Viros, A., Pedersen, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.006 · Cited by 212
“We also assessed SRC inhibitor 1, a selective SFK inhibitor (Bain et al., 2007) in these resistant cells.”
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
Bettayeb, K., Oumata, N., Echalier, A., Ferandin, Y., Endicott, J. A., Galons, H., & Meijer, L. (2008) · Oncogene · doi:10.1038/onc.2008.191 · Cited by 184
Koska, J., Sands, M., Burciu, C., D’Souza, K. M., Raravikar, K., Liu, J., Truran, S., Franco, D. A., Schwartz, E. A., Schwenke, D. C., et al. (2015) · Diabetes · doi:10.2337/db14-0976 · Cited by 174
“To exclude the possibility that CC might have modulated exenatide’s action through inhibition of other kinase pathways (45), we knocked down transcription of AMPKa in HUVECs and found reductions in exenatide-induced NO production in cells lacking AMPKa.”
BackgroundPehmøller, C., Treebak, J. T., Birk, J. B., Chen, S., MacKintosh, C., Hardie, D. G., Richter, E. A., & Wojtaszewski, J. F. P. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00115.2009 · Cited by 171
Dynamin I phosphorylation by GSK3 controls activity-dependent bulk endocytosis of synaptic vesicles
Clayton, E. L., Sue, N., Smillie, K. J., O'Leary, T., Bache, N., Cheung, G., Cole, A. R., Wyllie, D. J., Sutherland, C., Robinson, P. J., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2571 · Cited by 169
“The highly selective inhibitors of GSK3, CT99021 and AR-A014418, were synthesized as described previousl”
MethodThe role of skeletal muscle Akt in the regulation of muscle mass and glucose homeostasis
Jaiswal, N., Gavin, M. G., Quinn, W. J., Luongo, T. S., Gelfer, R. G., Baur, J. A., & Titchenell, P. M. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.08.001 · Cited by 167
LysRS Serves as a Key Signaling Molecule in the Immune Response by Regulating Gene Expression
Yannay-Cohen, N., Carmi-Levy, I., Kay, G., Yang, C. M., Han, J. M., Kemeny, D. M., Kim, S., Nechushtan, H., & Razin, E. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.05.019 · Cited by 166
Alimbetov, D., Davis, T., Brook, A. J. C., Cox, L. S., Faragher, R. G. A., Nurgozhin, T., Zhumadilov, Z., & Kipling, D. (2016) · Biogerontology · doi:10.1007/s10522-015-9610-z · Cited by 162
Min, W. W., Yuskaitis, C. J., Yan, Q., Sikorski, C., Chen, S., Jope, R. S., & Bauchwitz, R. P. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.09.017 · Cited by 146
Panja, D., Kenney, J. W., D’Andrea, L., Zalfa, F., Vedeler, A., Wibrand, K., Fukunaga, R., Bagni, C., Proud, C. G., & Bramham, C. R. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.016 · Cited by 143
AMPK-independent induction of autophagy by cytosolic Ca2+ increase
Grotemeier, A., Alers, S., Pfisterer, S. G., Paasch, F., Daubrawa, M., Dieterle, A., Viollet, B., Wesselborg, S., Proikas-Cezanne, T., & Stork, B. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.01.015 · Cited by 143
Roscovitine-Derived, Dual-Specificity Inhibitors of Cyclin-Dependent Kinases and Casein Kinases 1
Oumata, N., Bettayeb, K., Ferandin, Y., Demange, L., Lopez-Giral, A., Goddard, M.-L., Myrianthopoulos, V., Mikros, E., Flajolet, M., Greengard, P., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800109e · Cited by 139
CREB expression mediates amyloid β-induced basal BDNF downregulation
Rosa, E., & Fahnestock, M. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.014 · Cited by 138
Hämmerle, B., Ulin, E., Guimera, J., Becker, W., Guillemot, F., & Tejedor, F. J. (2011) · Development · doi:10.1242/dev.066167 · Cited by 137
“Mnb/Dyrk1a LoF experiments in the chick spinal cord were performed using two specific MNB/DYRK1A kinase inhibitors: harmine (Bain et al., 2007; Sitz et al., 2008; Göckler et al., 2009) and EGCG (Bain et al., 2003; Adayev et al., 2006; Guedj et al., 2009) (for a review, see Becker and Sippl, 2011).”
MethodEMD638683, a Novel SGK Inhibitor with Antihypertensive Potency
Ackermann, T. F., Boini, K. M., Beier, N., Scholz, W., Fuchß, T., & Lang, F. (2011) · Cellular Physiology and Biochemistry · doi:10.1159/000331722 · Cited by 121
The hyaluronidase, TMEM2, promotes ER homeostasis and longevity independent of the UPRER
Schinzel, R. T., Higuchi-Sanabria, R., Shalem, O., Moehle, E. A., Webster, B. M., Joe, L., Bar-Ziv, R., Frankino, P. A., Durieux, J., Pender, C., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.018 · Cited by 117
Koike, H., Iijima, M., & Chaki, S. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.034 · Cited by 114
Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor
Thomson, D. W., Poeckel, D., Zinn, N., Rau, C., Strohmer, K., Wagner, A. J., Graves, A. P., Perrin, J., Bantscheff, M., Duempelfeld, B., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00027 · Cited by 103
Andreozzi, F., Raciti, G. A., Nigro, C., Mannino, G. C., Procopio, T., Davalli, A. M., Beguinot, F., Sesti, G., Miele, C., & Folli, F. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0985-7 · Cited by 102
AMPK and the neuroendocrine regulation of appetite and energy expenditure
Stark, R., Ashley, S. E., & Andrews, Z. B. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.06.012 · Cited by 94
Yin, X., Jin, N., Shi, J., Zhang, Y., Wu, Y., Gong, C.-X., Iqbal, K., & Liu, F. (2017) · Scientific Reports · doi:10.1038/s41598-017-00682-y · Cited by 93
Identification of Small Molecule Inhibitors of Phosphatidylinositol 3-Kinase and Autophagy
Farkas, T., Daugaard, M., & Jäättelä, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.269134 · Cited by 91
Zhou, B., Li, H., Xu, L., Zang, W., Wu, S., & Sun, H. (2013) · Endocrinology · doi:10.1210/en.2012-2144 · Cited by 86
Hypothalamic AMP-Activated Protein Kinase Regulates Glucose Production
Yang, C. S., Lam, C. K. L., Chari, M., Cheung, G. W. C., Kokorovic, A., Gao, S., Leclerc, I., Rutter, G. A., & Lam, T. K. T. (2010) · Diabetes · doi:10.2337/db10-0221 · Cited by 86
Glycogen synthase kinase-3 is an early determinant in the differentiation of pathogenic Th17 cells
Beurel, E., Yeh, W.-I., Michalek, S. M., Harrington, L. E., & Jope, R. S. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003511 · Cited by 86
Watterson, D. M., Grum-Tokars, V. L., Roy, S. M., Schavocky, J. P., Bradaric, B. D., Bachstetter, A. D., Xing, B., Dimayuga, E., Saeed, F., Zhang, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066226 · Cited by 80
Panayiotou, R., Miralles, F., Pawlowski, R., Diring, J., Flynn, H. R., Skehel, M., & Treisman, R. (2016) · eLife · doi:10.7554/elife.15460 · Cited by 79
Green, C. J., Macrae, K., Fogarty, S., Hardie, D. G., Sakamoto, K., & Hundal, H. S. (2011) · Biochemical Journal · doi:10.1042/bj20101517 · Cited by 78
Atas-Ozcan, H., Brault, V., Duchon, A., & Herault, Y. (2021) · Genes · doi:10.3390/genes12111833 · Cited by 78
Genheden, M., Kenney, J. W., Johnston, H. E., Manousopoulou, A., Garbis, S. D., & Proud, C. G. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2641-14.2015 · Cited by 78
Rajamäki, K., Mäyränpää, M. I., Risco, A., Tuimala, J., Nurmi, K., Cuenda, A., Eklund, K. K., Öörni, K., & Kovanen, P. T. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.307312 · Cited by 75
Ketamine Influences CLOCK:BMAL1 Function Leading to Altered Circadian Gene Expression
Bellet, M. M., Vawter, M. P., Bunney, B. G., Bunney, W. E., & Sassone-Corsi, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023982 · Cited by 70
Jansen, T., Kvandová, M., Daiber, A., Stamm, P., Frenis, K., Schulz, E., Münzel, T., & Kröller-Schön, S. (2020) · Antioxidants · doi:10.3390/antiox9060525 · Cited by 68
Akt acutely activates the cholesterogenic transcription factor SREBP-2
Luu, W., Sharpe, L. J., Stevenson, J., & Brown, A. J. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.09.017 · Cited by 68
Kuwahara, A., Sakai, H., Xu, Y., Itoh, Y., Hirabayashi, Y., & Gotoh, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094408 · Cited by 66
Beggs, J. E., Tian, S., Jones, G. G., Xie, J., Iadevaia, V., Jenei, V., Thomas, G., & Proud, C. G. (2015) · Biochemical Journal · doi:10.1042/bj20141066 · Cited by 65
Wall, M., Poortinga, G., Stanley, K. L., Lindemann, R. K., Bots, M., Chan, C. J., Bywater, M. J., Kinross, K. M., Astle, M. V., Waldeck, K., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0404 · Cited by 64
Large-scale cytological profiling for functional analysis of bioactive compounds
Woehrmann, M. H., Bray, W. M., Durbin, J. K., Nisam, S. C., Michael, A. K., Glassey, E., Stuart, J. M., & Lokey, R. S. (2013) · Molecular BioSystems · doi:10.1039/c3mb70245f · Cited by 62
Senescent fibroblast-derived Chemerin promotes squamous cell carcinoma migration
Farsam, V., Basu, A., Gatzka, M., Treiber, N., Schneider, L. A., Mulaw, M. A., Lucas, T., Kochanek, S., Dummer, R., Levesque, M. P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13446 · Cited by 59
Akinaga, J., Lima, V., Kiguti, L. R. D. A., Hebeler-Barbosa, F., Alcántara-Hernández, R., García-Sáinz, J. A., & Pupo, A. S. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.082313 · Cited by 58
Vomocytosis of live pathogens from macrophages is regulated by the atypical MAP kinase ERK5
Gilbert, A. S., Seoane, P. I., Sephton-Clark, P., Bojarczuk, A., Hotham, R., Giurisato, E., Sarhan, A. R., Hillen, A., Velde, G. V., Gray, N. S., et al. (2017) · Science Advances · doi:10.1126/sciadv.1700898 · Cited by 54
Self-citationWang, S.-B., Venkatraman, V., Crowgey, E. L., Liu, T., Fu, Z., Holewinski, R., Ranek, M., Kass, D. A., O’Rourke, B., & Van Eyk, J. E. (2018) · Circulation Research · doi:10.1161/circresaha.118.312789 · Cited by 54
Goodlett, C. R., Stringer, M., LaCombe, J., Patel, R., Wallace, J. M., & Roper, R. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-67133-z · Cited by 43
Paradoxical activation of c-Src as a drug-resistant mechanism
Higuchi, M., Ishiyama, K., Maruoka, M., Kanamori, R., Takaori-Kondo, A., & Watanabe, N. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108876 · Cited by 31
Presence and utility of intrinsically disordered regions in kinases
Kathiriya, J. J., Pathak, R. R., Clayman, E., Xue, B., Uversky, V. N., & Davé, V. (2014) · Molecular BioSystems · doi:10.1039/c4mb00224e · Cited by 30
CK1α overexpression correlates with poor survival in colorectal cancer
Richter, J., Kretz, A.-L., Lemke, J., Fauler, M., Werner, J.-U., Paschke, S., Leithäuser, F., Henne-Bruns, D., Hillenbrand, A., & Knippschild, U. (2018) · BMC Cancer · doi:10.1186/s12885-018-4019-0 · Cited by 28
“Recently, D4476 has been described as a potent inhibitor of CK1α [24–26], although previously having been described as CK1δ/ε specific inhibitor [27, 28].”
BackgroundJNK Signaling is necessary for a Wnt and stem cell dependent regeneration program
Tejada-Romero, B., Carter, J.-M., Mihaylova, Y., Neumann, B., & Aboobaker, A. A. (2015) · Development · doi:10.1242/dev.115139 · Cited by 27
Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site
Rippin, I., Khazanov, N., Ben Joseph, S., Kudinov, T., Berent, E., Arciniegas Ruiz, S. M., Marciano, D., Levy, L., Gruzman, A., Senderowitz, H., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228709 · Cited by 25
Miglianico, M., Nicolaes, G. A. F., & Neumann, D. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01201 · Cited by 24
Amelioration of amyloid β‐FcγRIIb neurotoxicity and tau pathologies by targeting LYN
Gwon, Y., Kim, S.-H., Kim, H. T., Kam, T.-I., Park, J., Lim, B., Cha, H., Chang, H.-J., Hong, Y. R., & Jung, Y.-K. (2019) · The FASEB Journal · doi:10.1096/fj.201800926r · Cited by 20
Uranbileg, B., Yamamoto, H., Park, J.-H., Mohanty, A. R., Arakawa-Takeuchi, S., Jinno, S., & Okayama, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.318295 · Cited by 19
Jensen, H. A., Styskal, L. E., Tasseff, R., Bunaciu, R. P., Congleton, J., Varner, J. D., & Yen, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058621 · Cited by 18
“PP2 is a pyrazolopyrimidine compound that is a potent inhibitor for all SFK members [25,26].”
BackgroundWeng, W., Chen, Y., Wang, M., Zhuang, Y., & Behnisch, T. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00247 · Cited by 14
Serum/glucocorticoid regulated kinase 1 (SGK1) in neurological disorders: pain or gain
Howard, P. G., Zou, P., Zhang, Y., Huang, F., Tesic, V., Wu, C. Y.-C., & Lee, R. H.-C. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114973 · Cited by 13
Kjærgaard, J., Lindqvist, C. B., Quesada, J. P., Jessen, S., Schlabs, F., Ehrlich, A. M., Yonamine, C. Y., García-Ureña, M., Schmalbruch, J. H., Small, L., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102163 · Cited by 11
Metadata
- Authors
- Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P.
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2007-11-28
- Volume
- 408
- Issue
- 3
- Pages
- 297-315
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- OpenAlex
- W2046822015
- Cited by
- 2,520
- References
- 82
- FWCI
- 64.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.